Monday - December 12, 2016

Robert LaCaze to be Executive Vice President of New Oncology Strategic Business Unit at Pharmaceuticals Division of Bayer

Leverkusen, December 12, 2016 – Effective February 1, 2017, Robert LaCaze will become Executive Vice President of the new Oncology Strategic Business Unit at the Pharmaceuticals Division of Bayer. This new unit will enable the company to strategically manage and deliver upon its growing oncology portfolio including Nexavar®, Xofigo® and Stivarga® as well as its early and late stage development candidates with a focused and integrated approach in a highly competitive and rapidly evolving environment. The unit will combine Experimental Medicine Oncology, Clinical Pharmacology Oncology, early and late Project Management Oncology, Oncology Strategic Regulatory Affairs and Clinical Development Oncology. In addition the unit will include Oncology Strategic Marketing, Oncology Access and Pricing, Medical Affairs for Oncology globally, early oncology commercialization and certain operational functions. The new unit’s operating model will especially support accelerated development of new therapeutic options for patients to fight cancer.

LaCaze is currently Senior Vice President, Head of the Global Oncology Therapeutic Area within the Pharmaceuticals Division at Bayer. In his new role, he will be a member of the Pharmaceuticals Division’s Executive Committee which is led by Dieter Weinand, Bayer AG Board Member and responsible for Pharmaceuticals.

“We are delighted to have an executive with Robert LaCaze’s experience and talent lead the Oncology Strategic Business Unit,” said Dieter Weinand, Bayer AG Board Member and responsible for Pharmaceuticals. “I am confident that he will contribute his expertise and foresight to help strengthen our efforts in the fight against cancer.”

Prior to joining Bayer in 2015, LaCaze was at Bristol-Myers Squibb where he held the position as Senior Vice President, Head of Product and Portfolio Strategy in Princeton, New Jersey, United States of America. He has more than 27 years of experience in various executive roles in the pharmaceutical industry. The majority of his career has been spent in oncology with a focus on global strategy, operations, global strategic product launches including small molecules, biologics, and immuno-oncology. LaCaze earned a bachelor’s degree in Marketing from Louisiana Tech University, in Ruston, Louisiana, United States of America.

About Oncology at Bayer
Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer includes three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways, with the potential to impact the way that cancer is treated.

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.

Our online press service is just a click away: press.bayer.com
Follow us on Facebook: http://www.facebook.com/pharma.bayer
Follow us on Twitter: https://twitter.com/BayerPharma


Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Download Center


 
0
  file(s) collected
View Download Center

Contact


Last updated: December 19, 2016 Copyright © Bayer AG